Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYMPT-X + Dipeptiven is a perioperative glutamine supplementation (PGS) regimen investigated by National Taiwan University Hospital for its potential to mitigate sarcopenia and restore psoas muscle atrophy in patients with gastric adenocarcinoma undergoing gastrectomy. The intervention consists of two distinct components: Sympt-X, an oral glutamine powder (10 g per dose) taken three times daily for 28 days, and Dipeptiven, an intravenous solution containing the dipeptide N(2)-L-alanyl-L-glutamine administered for 5 days during the inpatient period. Glutamine is a conditionally essential amino acid that serves as a critical substrate for protein synthesis and a regulator of metabolic pathways. In catabolic states such as major surgery or cancer, exogenous glutamine supplementation is thought to stimulate muscle protein synthesis and inhibit protein degradation, thereby improving surgical outcomes and physical recovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SYMPT-X + Dipeptiven.